Sepsivac

rdf:langString Sepsivac

rdf:langString Mycobacterium w

rdf:langString Sepsivac is a drug developed by Cadila Pharmaceuticals to treat gram-negative sepsis. The active ingredient is heat-killed Mycobacterium w, a non-pathogenic strain of Mycobacterium. As an immunomodulatory, it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis. Sepsivac is a drug developed by CSIR and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme. In many cases, Sepsivac has proven to provide effective care and relief to COVID patients. Sepsivac is approved by the Drug Controller General of India (DCGI) for treatment of sepsis or septic shock.